Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureas.
This study aimed to assess the economic effect of adding either a thiazolidinedione (TZD) or metformin to the initial sulfonylurea therapy in patients with type 2 diabetes. Researchers identified patients newly diagnosed with type 2 diabetes who initiated therapy with a sulfonylurea during a four-year period from a Medicaid claims database. They then followed these patients after physicians added either a TZD or metformin to the regimen and assessed type 2 diabetes-related costs in the 12-month follow-up period. Multivariate results indicated that patients augmented with metformin incurred 33.3% lower total diabetes-related costs, compared with those augmented with a TZD (P < .001). The study results can aid in making formulary decisions and developing treatment algorithms for step-wise management of type 2 diabetes.